EXHIBIT 99.1

Unaudited Pro Forma Consolidated Financial Information

     The following unaudited pro forma condensed consolidated financial information reflects our pro forma financial position as of September 30, 2006, and our pro forma results of operations for the nine months ended September 30, 2006 and for the fiscal years ended December 31, 2005, 2004 and 2003, giving effect to the sale of 14,501,000 shares of Omega Protein Corporation (“Omega”) common stock. This sale was consummated in two transactions. The first transaction was completed on November 28, 2006, through the sale of 9,268,292 shares back to Omega for a gross purchase price of $47.5 million. The second transaction was completed on December 4, 2006, through the private resale of 5,232,708 shares to a group of institutional investors for a gross purchase price of approximately $29.0 million.

     Historical financial data used to prepare the pro forma financial statements were derived from the audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2005, and the unaudited financial statements in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2006. This unaudited pro forma condensed consolidated financial information should be read in conjunction with our historical consolidated financial statements and the notes thereto. The unaudited pro forma condensed consolidated financial information set forth below is not necessarily indicative of what the actual results of operations would have been had these events occurred as of the dates indicated and is not intended to be a projection of future results.

     The unaudited pro forma condensed consolidated balance sheet and unaudited pro forma condensed consolidated statements of operations are based on assumptions and approximations that our management believes are reasonable. They do not reflect in precise numerical terms the impact of the transactions on the historical financial statements, and are subject to change. Such pro forma financial information should not be used as a basis for forecasting the future operations of Zapata. The pro forma financial information is presented for illustrative purposes only, and is not necessarily indicative of any future results of operations, or the results that might have occurred if the sale of 14,501,000 shares of Omega Protein common stock had actually occurred on the indicated dates.

ZAPATA CORPORATION
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
September 30, 2006

				Pro Forma Adjustments
	Zapata
	Corporation			Omega Protein			Other Pro Forma			Pro Forma
	(Note 1)			(Note 2)			Adjustments			(Note 3)
	(In thousands, except per share amounts)
ASSETS
Current assets:
Cash and cash equivalents	$	90,072		$	13,542		$	75,541	(a)	$	152,071
Accounts receivable, net		21,484			21,300			—			184
Inventories, net		59,734			59,734			—			—
Prepaid expenses and other current assets		3,553			2,614			—			939
Total current assets		174,843			97,190			75,541			153,194
Other assets, net		34,088			15,541			184	(b)		18,731
Property, plant and equipment, net		89,993			101,071			11,082	(c)		4
Total assets	$	298,294		$	213,802		$	86,807		$	171,929
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt	$	2,426		$	2,426		$	—		$	—
Accounts payable		2,396			2,303			519	(d)		613
Accrued and other current liabilities		28,242			25,421			—			2,821
Total current liabilities		33,064			30,150			519			3,434
Long-term debt		25,823			25,823			—			—
Pension liabilities		10,341			9,492			—			849
Other liabilities and deferred taxes		395			—			—			395
Total liabilities		69,623			65,465			519			4,678
Commitments and contingencies
Minority interest		63,198			—			(63,163	) (e)		35
Stockholders’ equity:
Preferred stock, $.01 par; 1,600,000 shares authorized; none issued or outstanding		—			—			—			—
Preference stock, $.01 par; 14,400,000 shares authorized; none issued or outstanding		—			—			—			—
Common stock, $0.01 par, 132,000,000 shares authorized; 24,614,536 shares issued; and 19,182,456 shares outstanding		246			257			257	(f)		246
Capital in excess of par value		164,902			117,517			117,036	(g)		164,421
Retained earnings		37,377			40,221			37,306	(h)		34,462
Treasury stock, at cost, 5,432,080 shares		(31,668	)		(2,035	)		(2,035	) (f)		(31,668	)
Accumulated other comprehensive loss		(4,754	)		(7,623	)		(3,113	) (f)		(244	)
Total stockholders’ equity		166,103			148,337			149,451			167,217
Total liabilities and stockholders’ equity	$	298,294		$	213,802		$	86,807		$	171,929

Note 1:	Represents Zapata Corporation’s reported unaudited condensed consolidated balance sheet, which includes Zapata’s 57% ownership of Omega Protein.
Note 2:	Represents Omega Protein’s unaudited condensed consolidated balance sheet.

Note 3:   Represents Zapata Corporation’s unaudited pro forma condensed consolidated balance sheet assuming Zapata sold 14,501,000 shares of Omega Protein on September 30, 2006.
(a)	Reflects the net proceeds received for all of Zapata Corporation’s 14,501,000 shares of Omega Protein.
(b)	Reflects a net adjustment to deferred tax assets. Deferred tax liabilities were reduced to reflect the elimination of the book vs. tax basis difference related to Omega Protein. Deferred tax assets were reduced to reflect the utilization of net operating losses which would be used to offset the majority of taxes payable on the sale of Omega Protein.
(c)	Represents an impairment charge recognized in the third quarter of 2006 to reduce the carrying value of Zapata Corporation’s investment in Omega protein to fair value, through a reduction of Omega’s long-lived assets.
(d)	Reflects the estimated alternative minimum taxes and general and administrative costs to dispose of Omega Protein.
(e)	Reflects the elimination of Minority Interest related to Omega Protein.
(f)	Reflects Omega pro forma adjustments in equity which are eliminated in consolidation.
(g)	Reflects the elimination of the investment in Omega Protein.
(h)	Reflects the change in net income resulting from the pro forma adjustments to the September 30, 2006 unaudited pro forma condensed consolidated balance sheet.

ZAPATA CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the Nine Months Ended September 30, 2006

				Pro Forma Adjustments
	Zapata			Omega			Other Pro
	Corporation			Protein			Forma			Pro Forma
	(Note 1)			(Note 2)			Adjustments			(Note 3)
	(In thousands, except per share amounts)
Revenues	$	113,730		$	113,730		$	—		$	—
Cost of revenues		94,061			94,061			—			—
Gross profit		19,669			19,669			—			—
Operating expenses:
Selling, general and administrative		14,633			10,473			—			4,160
Loss resulting from natural disaster		1,351			1,351			—			—
Impairment of long-lived assets		11,082			—			11,082	(a)		—
Total operating expenses		27,066			11,824			11,082			4,160
Operating income (loss)		(7,397	)		7,845			(11,082	)		(4,160	)
Other income (expense):
Interest income		3,250			507			—			2,743
Interest expense		(1,550	)		(1,550	)		—			—
Other, net		80			(159	)		—			239
		1,780			(1,202	)		—			2,982
Income (loss) before income taxes and minority interest		(5,617	)		6,643			(11,082	)		(1,178	)
(Provision) benefit for income taxes		(1,991	)		(1,675	)		3,255	(b)		411
Minority interest in net income of consolidated subsidiaries		(2,090	)		(2,091	)		—			1
(Loss) income from continuing operations	$	(5,716	)	$	2,877		$	(7,827	)	$	(766	)
Loss from continuing operations per share – basic and diluted (Note 4)	$	(0.30	)							$	(0.04	)
Weighted average common shares outstanding:
Basic		19,182									19,182
Diluted		19,182									19,182

Note 1:	Represents Zapata Corporation’s reported unaudited condensed consolidated statements of operations which includes Zapata’s ownership of Omega Protein.
Note 2:	Represents the unaudited condensed consolidated statement of operations of Omega Protein, including minority interest which represents the minority stockholders’ interest in the net income of Omega Protein.
Note 3:	Represents Zapata Corporation’s unaudited pro forma condensed consolidated statement of operations assuming Zapata sold 14,501,000 shares of Omega on January 1, 2003.
Note 4:	Basic loss from continuing operations per share was computed by dividing the loss from continuing operations by the weighted average common shares outstanding during the period. Diluted loss from continuing operations per share excluded options that had an exercise price greater than the average market price of the common shares for the period, or options that would be antidilutive to the loss.

(a)	Represents an impairment charge recognized in the third quarter of 2006 to reduce the carrying value of Zapata Corporation’s investment in Omega Protein to fair value, through a reduction of Omega’s long-lived assets.
(b)	Represents an adjustment for amounts recorded by Zapata Corporation for the adjusted post-transaction book vs. tax basis difference related to Omega Protein in accordance with SFAS No. 109.

ZAPATA CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the Year Ended December 31, 2005

				Pro Forma Adjustments
	Zapata			Omega			Other Pro
	Corporation			Protein			Forma			Pro Forma
	(Note 1)			(Note 2)			Adjustments			(Note 3)
	(In thousands, except per share amounts)
Revenues	$	109,896		$	109,896		$	—		$	—
Cost of revenues		91,985			91,985			—			—
Gross profit		17,911			17,911			—			—
Operating expenses:
Selling, general and administrative		18,572			13,055			—			5,517
Loss resulting from natural disaster		15,743			15,743			—			—
Total operating expenses		34,315			28,798			—			5,517
Operating loss		(16,404	)		(10,887	)		—			(5,517	)
Other income (expense):
Interest income		1,911			615			—			1,296
Interest expense		(1,255	)		(1,255	)		—			—
Other, net		199			73			—			126
		855			(567	)		—			1,422
Loss before income taxes and minority interest		(15,549	)		(11,454	)		—			(4,095	)
Benefit for income taxes		6,748			4,268			1,498	(a)		982
Minority interest in net loss of consolidated subsidiaries		3,027			3,026			—			1
Loss from continuing operations	$	(5,774	)	$	(4,160	)	$	(1,498	)	$	(3,112	)
Loss from continuing operations per share – basic and diluted (Note 4)	$	(0.30	)							$	(0.16	)
Weighted average common shares outstanding:
Basic		19,136									19,136
Diluted		19,136									19,136

Note 1:	Represents Zapata Corporation’s reported unaudited condensed consolidated statements of operations which includes Zapata’s ownership of Omega Protein.
Note 2:	Represents the unaudited condensed consolidated statement of operations of Omega Protein, including minority interest which represents the minority stockholders’ interest in the net loss of Omega Protein.
Note 3:	Represents Zapata Corporation’s unaudited pro forma condensed consolidated statement of operations assuming Zapata sold 14,501,000 shares of Omega on January 1, 2003.
Note 4:	Basic loss from continuing operations per share was computed by dividing the loss from continuing operations by the weighted average common shares outstanding during the year. Diluted loss

	from continuing operations per share excluded options that had an exercise price greater than the average market price of the common shares for the period, or options that would be antidilutive to the loss.
(a)	Represents an adjustment for amounts recorded by Zapata Corporation of the adjusted book vs. tax basis difference related to Omega Protein in accordance with SFAS No. 109.

ZAPATA CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the Year Ended December 31, 2004

				Pro Forma Adjustments
	Zapata			Omega			Other Pro
	Corporation			Protein			Forma			Pro Forma
	(Note 1)			(Note 2)			Adjustments			(Note 3)
	(in thousands, except per share amounts)
Revenues	$	119,645		$	119,645		$	—		$	—
Cost of revenues		104,237			104,237			—			—
Gross profit		15,408			15,408			—			—
Operating expenses:
Selling, general and administrative		14,496			10,120			—			4,376
Total operating expenses		14,496			10,120			—			4,376
Operating income (loss)		912			5,288			—			(4,376	)
Other income (expense):
Interest income		992			594			—			398
Interest expense		(965	)		(965	)		—			—
Other, net		(221	)		(221	)		—			—
		(194	)		(592	)		—			398
Income (loss) before income taxes and minority interest		718			4,696			—			(3,978	)
(Provision) benefit for income taxes		(955	)		(1,494	)		(148	)(a)		687
Minority interest in net income of consolidated subsidiaries		(1,283	)		(1,287	)		—			4
(Loss) income from continuing operations	$	(1,520	)	$	1,915		$	(148	)	$	(3,287	)
Loss from continuing operations per share – basic and diluted (Note 4)	$	(0.07	)							$	(0.17	)
Weighted average common shares outstanding:
Basic		19,131									19,131
Diluted		19,131									19,131

Note 1:	Represents Zapata Corporation’s reported unaudited condensed consolidated statements of operations which includes Zapata’s ownership of Omega Protein.
Note 2:	Represents the unaudited condensed consolidated statement of operations of Omega Protein, including minority interest which represents the minority stockholders’ interest in the net income of Omega Protein.
Note 3:	Represents Zapata Corporation’s unaudited pro forma condensed consolidated statement of operations assuming Zapata sold 14,501,000 shares of Omega on January 1, 2003.
Note 4:	Basic loss from continuing operations per share was computed by dividing the loss from continuing operations by the weighted average common shares outstanding during the year. Diluted loss from continuing operations per share excluded options that had an exercise price greater than the average market price of the common shares for the period, or options that would be antidilutive to the loss.
(a)	Represents an adjustment for amounts recorded by Zapata Corporation of the adjusted book vs. tax basis difference related to Omega Protein in accordance with SFAS No. 109.

ZAPATA CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the Year Ended December 31, 2003

				Pro Forma Adjustments
	Zapata						Other Pro
	Corporation			Omega Protein			Forma			Pro Forma
	(Note 1)			(Note 2)			Adjustments			(Note 3)
	(in thousands, except per share amounts)
Revenues	$	117,926		$	117,926		$	—		$	—
Cost of revenues		99,028			99,028			—			—
Gross profit		18,898			18,898			—			—
Operating expenses:
Selling, general and administrative		13,068			9,369			—			3,699
Total operating expenses		13,068			9,369			—			3,699
Operating income (loss)		5,830			9,529			—			(3,699	)
Other income (expense):
Interest income		1,214			443			—			771
Interest expense		(1,134	)		(1,134	)		—			—
Other, net		(234	)		(234	)		—			—
		(154	)		(925	)		—			771
Income (loss) before income taxes and minority interest		5,676			8,604			—			(2,928	)
(Provision) benefit for income taxes		(3,017	)		(2,806	)		(4,514	)(a)		4,303
Minority interest in net income of consolidated subsidiaries		(2,305	)		(2,307	)		—			2
Income (loss) from continuing operations	$	354		$	3,491		$	(4,514	)	$	1,377
Income from continuing operations per share – basic and diluted (Note 4)	$	0.02								$	0.07
Weighted average common shares outstanding:
Basic		19,128									19,128
Diluted		19,244									19,244

Note 1:	Represents Zapata Corporation’s reported unaudited condensed consolidated statements of operations which includes Zapata’s ownership of Omega Protein.
Note 2:	Represents the unaudited condensed consolidated statement of operations of Omega Protein, including minority interest which represents the minority stockholders’ interest in the net income of Omega Protein.
Note 3:	Represents Zapata Corporation’s unaudited pro forma condensed consolidated statement of operations assuming Zapata sold 14,501,000 shares of Omega on January 1, 2003.
Note 4:	Basic income from continuing operations per share was computed by dividing the income from continuing operations by the weighted average common shares outstanding during the year. Diluted income from continuing operations per share excluded options that had an exercise price greater than the average market price of the common shares for the period.
(a)	Represents an adjustment for amounts recorded by Zapata Corporation for the adjusted book vs. tax basis difference related to Omega Protein in accordance with SFAS No. 109.